ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Wegener’s granulomatosis"

  • Abstract Number: 877 • 2015 ACR/ARHP Annual Meeting

    Improved Survival in Granulomatosis with Polyangiitis: A Population-Based Study

    Ju Ann1, Hyon K. Choi2, Sharan K. Rai3, Eric C. Sayre4 and J Antonio Avina-Zubieta5,6, 1Experimental Mediine, University of British Columbia, Richmond, BC, Canada, 2Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, 4Arthritis Research Canada, Richmond, BC, Canada, 5Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, 6Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada

    Background/Purpose: Granulomatosis with Polyangiitis (GPA) is associated with an increased risk of mortality. However, recent mortality trends in GPA are largely unknown, particularly in the…
  • Abstract Number: 888 • 2015 ACR/ARHP Annual Meeting

    Plasma Exchanges to Treat Primary Systemic Necrotizing Vasculitides: Data from a French Nationwide Study

    Gonzalo De Luna1, Dominique Chauveau2, Julien Aniort3, Pierre-Louis Carron4, Pierre Gobert5, Alexandre Karras6, Sylvain Adam-Marchand7, Francois Maurier8, Pierre-Yves Hatron9, Alexandre Mania10, Guillaume Le Guenno11, Stéphane Ballly12, Boris Bienvenu13, Eric Cardineau14, Tiphaine Goulenok15, Noémie Jourde-Chiche Sr.16, Maxime Samson17, Antoine Huart18, Jacques Pourrat19, Aurelien Tiple20, Olivier Aumaître21, Xavier Puéchal22, Farhad Heshmati23, Claire Le Jeunne24, Luc Mouthon25, Loïc Guillevin26 and Benjamin Terrier22, 1Medecine Interne, Cochin University Hospital, Paris, France, 2CH Toulouse, Toulouse, France, 3CHU, Clermont-Ferrand, France, 4Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, 5Nephrology, Centre Hospitalier d'Avignon, Avignon, France, 6George Pompidou European Hospital, Paris, France, 7Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France, 8HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, 9Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, 10Hôpital Gabriel Montpied, Clermont-Ferrand, France, 11Internal Medicine department, Clermont-Ferrand, France, 12CH, Chambéry, France, 13Internal Medicine, Hospital Caen, Caen, France, 14CH, Alencon, France, 15University Paris Diderot - APHP - Bichat Hospital, aris, France, 16Nephrology, Aix-Marseille Université - APHM, Marseille, France, 17Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 18CHU, Toulouse, France, 19Nephrology, Rangeuil Hospital, Paris, France, 20Nephrology, CHU, Clermont-Ferrand, France, 21Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, 22Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, 23Cochin Hospital, Paris, France, 24Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, 25Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, 26Internal Medicine, Hopital Cochin, Paris, France

    Background/Purpose: Plasma exchange (PE) is usually used to treat severe primary systemic necrotizing vasculitides (SNVs) and/or virus-induced vasculitides. Only severe renal insufficiency (serum creatinine (SCR)…
  • Abstract Number: 1082 • 2015 ACR/ARHP Annual Meeting

    ANCA-Negative and Myeloperoxidase-ANCA-Positive Patients with Granulomatosis with Polyangiitis: Clinical Manifestations and Risk of Relapse

    Eli Miloslavsky1, Na Lu2, Sebastian Unizony3, Hyon K. Choi3, Peter A. Merkel4, Philip Seo5, Robert F. Spiera6, Carol A. Langford7, Gary S. Hoffman7, Cees Kallenberg8, E. William St.Clair9, Nadia Tchao10, Fernando Fervenza11, Paul A. Monach12, Ulrich Specks13 and John H. Stone14, 1Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 5Division of Rheumatology, Johns Hopkins, Baltimore, MD, 6Rheumatology, Hospital for Special Surgery, New York, NY, 7Rheumatology, Cleveland Clinic, Cleveland, OH, 8Rheumatology/Clin Immunol AA21, Univer Med Center Groningen, Groningen, Netherlands, 9Rheumatology and Immunology, Duke University, Durham, NC, 10ITN, San Francisco, CA, 11Mayo Clinic, Rochester, MN, 12Rheumatology, Boston University School of Medicine, Boston, MA, 13Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, 14Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Recent studies in ANCA-associated vasculitis (AAV) have suggested that classification based on ANCA type (PR3 versus MPO) may represent a more clinically relevant division…
  • Abstract Number: 1270 • 2015 ACR/ARHP Annual Meeting

    Low Socioeconomic Status As a Predictor of Long-Term Direct Medical Costs Following Diagnosis of Granulomatosus with Polyangiitis: A General Population-Based Cohort Study

    Natalie McCormick1, Carlo Marra2 and J Antonio Avina-Zubieta3, 1Faculty of Pharmaceutical Sciences, University of British Columbia/Arthritis Research Canada, Vancouver, BC, Canada, 2Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, 3Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Estimates of the healthcare costs of Granulomatosus with polyangiitis (GPA) and predictors of costs are scarce.  In particular, while socioeconomic status (SES) is associated…
  • Abstract Number: 1865 • 2014 ACR/ARHP Annual Meeting

    Increased Risk of Myocardial Infarction and Cerebrovascular Accidents after Diagnosis of Granulomatosis with Polyangiitis: A General Population-Based Cohort Study

    Neda Amiri1, Natasha Dehghan2, Eric C. Sayre3, Kamran Shojania1 and J. Antonio Avina-Zubieta4, 1Rheumatology, University of British Columbia, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, BC, Canada, 3Arthritis Research Centre of Canada, Richmond, BC, Canada, 4Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada

    Background/Purpose Limited literature is available on the incidence of myocardial infarction (MI) and cerebrovascular accidents (CVA) in patients with Granulomatosis with Polyangiitis (GPA).  We assessed…
  • Abstract Number: 1786 • 2014 ACR/ARHP Annual Meeting

    Vasculitis As Underlying Cause of Death in the United States: 1999 – 2010

    Alicia Rodriguez-Pla1, Paul A. Monach2 and Jose Rossello-Urgell3, 1Rheumatology, Boston University, Boston, MA, 2Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, 3Baylor Research Institut, Baylor Institute for Immunology Research, Dallas, TX

    Background/Purpose Current data on mortality rates of primary vasculitis, which were tradionally associated with a dreadful prognosis, are limited. Therefore, we aimed to estimate the mortality rates…
  • Abstract Number: 1776 • 2014 ACR/ARHP Annual Meeting

    Factors Predictive of ANCA-Associated Vasculitis Relapse in Patients Given Rituximab-Maintenance Therapy

    Benjamin Terrier1, Christian Pagnoux2, Guillaume Geri3, Alexandre Karras4, Chahéra Khouatra5, Olivier Aumaitre6, Pascal Cohen7, Francois Maurier8, Olivier Decaux9, Hélène Desmurs-Clavel10, Pierre Gobert11, Thomas Quemeneur12, Claire Blanchard-Delaunay13, Pascal Godmer14, Xavier Puéchal7, Luc Mouthon7 and Loïc Guillevin for the French Vasculitis Study Group7, 1National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 2Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 3Intensive Care Unit, Cochin Hospital, Paris, France, 4Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, 5CHU Louis Pradel, Lyon, Lyon, France, 6Internal Medicine, CHU, Clermont-Ferrand, France, 7National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 8HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, 9Department of Internal Medicine, Rennes University Hospital, Rennes, France, 10University of Lyon, LYON, France, 11Nephrology, Centre Hospitalier d'Avignon, Avignon, France, 12Internal Medicine, CH, Valenciennes, France, 13Internal Medicine, Hôpital de Niort, Niort, France, 14Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France

    Background/Purpose Rituximab (RTX) was shown to be as effective as cyclophosphamide to induce remission in patients with ANCA-associated vasculitis (AAV). The prospective MAINRITSAN trial compared…
  • Abstract Number: 1770 • 2014 ACR/ARHP Annual Meeting

    Increased Risk of Chronic Obstructive Pulmonary Disease in Granulomatosis with Polyangiitis: A General Population-Based Study

    Neda Amiri1, Mohsen Sadatsafavi2, Eric C. Sayre3, John M. Esdaile4 and J. Antonio Avina-Zubieta2,5, 1Rheumatology, University of British Columbia, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, BC, Canada, 3Arthritis Research Centre of Canada, Richmond, BC, Canada, 4Rheumatology, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, 5Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada

    Background/Purpose             Chronic obstructive pulmonary disease (COPD) is increasingly recognized as an inflammatory condition. We aimed to identify the risk of newly recorded COPD among…
  • Abstract Number: 1767 • 2014 ACR/ARHP Annual Meeting

    Granulomatosis with Polyangiitis (Wegener’s) According to Geographic Origin and Ethnicity: Clinical-Biological Presentation and Outcome

    Benjamin Terrier1, Christophe Deligny2, Xavier Puéchal3, Pascal Godmer4, Pierre Charles5, Gilles Hayem6, Bertrand Dunogué7, Pascal Cohen3, Serge Arfi8, Luc Mouthon3 and Loïc Guillevin for the French Vasculitis Study Group3, 1National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 2Internal Medicine, CHU Fort de France, Fort de France, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 4Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, 5Internal Medicine, Institut Mutualiste Montsouris, Paris, France, 6Rhumatologie, Hopital Bichat, Paris Cedex 18, France, 7Internal Medicine, Hôpital Cochin, Paris, France, 8Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique

    Background/Purpose Granulomatosis with polyangiitis (Wegener’s) (GPA) is an ANCA-associated vasculitis (AAV) predominantly affecting small-sized vessels, involving mainly the upper and lower respiratory tracts and kidneys.…
  • Abstract Number: 1758 • 2014 ACR/ARHP Annual Meeting

    Environmental Risk Factors for Granulomatous Polyangiitis (GPA): Southern Hemisphere Similar to Northern Hemisphere

    Lisa K. Stamp1, Peter T. Chapman2, Richard A. Watts3, Christopher Frampton1 and John L. O'Donnell4, 1Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, 2Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand, 3Rheumatology Department Ipswich Hospital and University of East Anglia, Ipswich, United Kingdom, 4Rheumatology Immunology & Allergy, Canterbury Health Laboratories, Christchurch, New Zealand

    Background/Purpose: GPA is a rare condition of unknown etiology. Prominent involvement of the upper and lower respiratory tracts suggests that inhaled antigens may trigger systemic…
  • Abstract Number: 1756 • 2014 ACR/ARHP Annual Meeting

    Molecular Diagnosis Reveals a Surprising Prevalence of Limited Gpa Among Patients with Orbital Inflammatory Diseases

    James T. Rosenbaum1, Dongseok Choi2, Christine Harrington3, Patrick Stauffer4, David Wilson5, Seema Gupta4, Roger Dailey4, John Ng4, Eric Steele4, Patrick Yeatts6, Peter Dolman7, Valerie White7, Gerald Harris8, Craig Czyz9, Jill Foster9, Deepak Edward10, Hind Alkatan10, Bobby Korn11, Don Kikkawa12, Dinesh Selva13, Sander Dubovy14, Chris Alabiad15, David Tse15, Michael Kazim16, Payal Patel16 and Stephen R. Planck17, 1OHSU, Portland, OR, 2Casey Eye Institute, Oregon Health and Science University, Portland, OR, 3Integrated Genomics, Oregon Health & Science University, Portland, OR, 4Oregon Health & Science University, Portland, OR, 5Casey Eye Institute/Ophthalmology, Oregon Health & Science University, Portland, OR, 6Ophthalmology, Wake Forest University, Winston-Salem, NC, 7University of British Columbia, Vancouver, BC, Canada, 8Medical College of Wisconsin, Milwaukee, WI, 9Ohio State Univeristy, Columbus, OH, 10King Khaled Eye Hospital, Riyadh, Saudi Arabia, 11University of California, San Diego, San Diego, CA, 12Ophthalmology, University of California, San Diego, San Diego, CA, 13Royal Adelaide Hospital, Adelaide, Australia, 14University of Miami, Miami, FL, 15Ophthalmology, University of Miami, Miami, FL, 16Columbia University, New York City, NY, 17Casey Eye Inst/Ophthalmology, Oregon Health & Science University, Portland, OR

    Background/Purpose: Gene expression profiling provides diagnostic and therapeutic information in several malignancies, but its role in evaluating inflammatory disease is relatively untested. We hypothesized that…
  • Abstract Number: 1763 • 2014 ACR/ARHP Annual Meeting

    Tobacco Differentially Affects the Clinical-Biological Phenotype of ANCA-Associated Vasculitides at Diagnosis

    Lucas Benarous1, Benjamin Terrier2, Bertrand Dunogué3, Pascal Cohen4, Xavier Puéchal4, Claire Le Jeunne4, Luc Mouthon4 and Loïc Guillevin for the French Vasculitis Study Group4, 1Cochin Hospital, Paris, France, 2National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 3Internal Medicine, Hôpital Cochin, Paris, France, 4National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France

    Background/Purpose Occupational and non-occupational exposures may play a role in the occurrence of ANCA-associated vasculitides (AAV) and affect their initial clinical-biological phenotype. Among these potential…
  • Abstract Number: 1236 • 2014 ACR/ARHP Annual Meeting

    IgG4 Immunostaining Is Common but Not Specific in Orbitbal Inflammatory Diseases

    James T. Rosenbaum1,2, Amanda Wong3, Patrick Stauffer3, Megan Troxell4, Donald Houghton5, Dongseok Choi6, Christine Harrington7, David Wilson8, Hans Grossniklaus9, Roger Dailey3, John Ng3, Eric Steele3, Patrick Yeatts10, Peter Dolman11, Valerie White11, Craig Czyz12, Jill Foster12, Deepak Edward13, Hind Alkatan13, Don Kikkawa14, Bobby Korn15, Dinesh Selva16, Gerald Harris17, Michael Kazim18, Payal Patel18 and Stephen R. Planck19, 1OHSU, Portland, OR, 2Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, 3Oregon Health & Science University, Portland, OR, 4Pathology, Oregon Health and Science University, Portland, OR, 5Pathology, Oregon Health & Science University, Portland, OR, 6Casey Eye Institute, Oregon Health and Science University, Portland, OR, 7Integrated Genomics, Oregon Health & Science University, Portland, OR, 8Casey Eye Institute/Ophthalmology, Oregon Health & Science University, Portland, OR, 9Ophthalmology, Emory University, Atlanta, GA, 10Ophthalmology, Wake Forest University, Winston-Salem, NC, 11University of British Columbia, Vancouver, BC, Canada, 12Ohio State Univeristy, Columbus, OH, 13King Khaled Eye Hospital, Riyadh, Saudi Arabia, 14Ophthalmology, University of California, San Diego, San Diego, CA, 15University of California, San Diego, San Diego, CA, 16Royal Adelaide Hospital, Adelaide, Australia, 17Medical College of Wisconsin, Milwaukee, WI, 18Columbia University, New York City, NY, 19Casey Eye Inst/Ophthalmology, Oregon Health & Science University, Portland, OR

    Background/Purpose: IgG4-related disease is an emerging clinical entity which frequently involves tissue within the orbit. In order to appreciate the implications of IgG4 immunostaining, we…
  • Abstract Number: 1861 • 2014 ACR/ARHP Annual Meeting

    The Role of Macrophage Migration Inhibitory Factor (MIF) and MIF Gene Polymorphisms in the Pathogenesis of Granulomatosis with Polyangiitis

    Antoine G. Sreih1, Rana Ezzeddine2, Juan Fan3, Lin Leng3, Simon Carette4, David Cuthbertson5, Gary S. Hoffman6, Nader A. Khalidi7, Carol A. Langford8, Carol McAlear9, Paul Monach10, Philip Seo11, Ulrich Specks12, Steven R. Ytterberg13, Peter A. Merkel14 and Richard Bucala15, 1Medicine/Division of Rheumatology, The University of Pennsylvania, Philadelphia, PA, 2Biostatistics, Bristol-Myers Squibb, Wallingford, CT, 3Yale University, New Haven, CT, 4Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 5Department of Biostatistics, University of South Florida, Tampa, FL, 6Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 7Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, 8Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 9Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, 10Rheumatology, Boston University, Boston, MA, 11Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 12Frederichs Dr NW, Mayo Clinic, Rochester, MN, 13Division of Rheumatology, Mayo Clinic, Rochester, MN, 14Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 15Rheum/Dept of Int Med, Yale University School of Med, New Haven, CT

    Background/Purpose: Macrophage Migration Inhibitory Factor (MIF) is an immunoregulatory cytokine that may play a central role in the pathogenesis of granulomatous diseases. Two functional polymorphisms…
  • Abstract Number: 1273 • 2013 ACR/ARHP Annual Meeting

    Granulomatosis With Polyangiitis In Children Is More Severe Than In Adults. A Long-Term, Single Center, Follow Up Study

    Francesco Zulian1, Grazia Minardo2, Valeria Carraro3, Franco Schiavon3 and Giorgia Martini4, 1PRINTO, Genoa, Italy, 2Department of Pediatrics, University of Padua, Padua, Italy, 3Rheumatology Clinic, University of Padova, Padova, Italy, 4Department of Pediatrics,, University of Padua, Padua, Italy

    Background/Purpose: Granulomatosis with polyangiitis (GPA) is a rare disease in childhood. Treatment strategies and clinical approach are still mostly derived from adult GPA studies. The…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology